Media Room

Here you can find news, a variety of media and other useful information on us

Featured articles

Ellipses Pharma explores a London Stock Exchange listing opportunity

Ellipses Pharma explores a London Stock Exchange listing opportunity London, November 18, 2026 Ellipses Pharma Limited ("Ellipses") the London-based global oncology drug development company with a pipeline of innovative programmes, today announced that the Company is exploring a listing opportunity on the main market of the London Stock Exchange. Ellipses has signed a non-binding Memorandum [...]

Read more

EP0062 TIP ASCO 2026 Poster

EP0062 TIP ASCO 2026 Poster {{ vc_btn: title=Download+as+PDF&style=custom&custom_background=%23000066&custom_text=%23ffffff&shape=round&size=lg&align=center&css=.vc_custom_1786109564984%7Bpadding-top%3A+15px+%21important%3B%7D&link=url%3Ahttps%253A%252F%252Fellipses.life%252Fwp-content%252Fuploads%252F2026%252F08%252FASCO26_EP0062-TIP_poster.pdf%7Ctarget%3A_blank }} About Ellipses Pharma Limited Ellipses Pharma is a global drug development company based in London, focused on accelerating the development of cancer treatments through an innovative drug development model that combines unbiased vetting to de-risk initial asset selection with an uninterrupted funding flow to minimise the [...]

Read more

EP0089 ASCO 2026 Poster

EP0089 ASCO 2026 Poster {{ vc_btn: title=Download+as+PDF&style=custom&custom_background=%23000066&custom_text=%23ffffff&shape=round&size=lg&align=center&css=.vc_custom_1786102071864%7Bpadding-top%3A+15px+%21important%3B%7D&link=url%3Ahttps%253A%252F%252Fellipses.life%252Fwp-content%252Fuploads%252F2026%252F08%252FEP0089-101_ASCO-2026-TiP-Poster.pdf%7Ctarget%3A_blank }} About Ellipses Pharma Limited Ellipses Pharma is a global drug development company based in London, focused on accelerating the development of cancer treatments through an innovative drug development model that combines unbiased vetting to de-risk initial asset selection with an uninterrupted funding flow to minimise the time [...]

Read more

Pivotal trial data for EP0031 in RET +ve advanced NSCLC, to be presented at ASCO 2026

Pivotal trial data for EP0031 in RET +ve advanced NSCLC, to be presented at ASCO 2026 London, May 22, 2026 Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive [...]

Read more

Want to learn more?